Last Update 21 Feb 26

Fair value Decreased 1.34%

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.

Analyst Commentary

Recent research on Pfizer highlights a split view, with some firms cautious on patent expirations and revenue visibility while others point to valuation support and pipeline moves as potential positives. Price targets in this latest batch of reports cluster around the mid 20s, with one firm lifting its target by US$3. This suggests a range of opinions on how effectively Pfizer can handle upcoming losses of exclusivity and reinvest in growth.

On the more cautious side, one bearish initiation set a US$25 target and an Underweight rating, citing major patent expirations that begin this year and accelerate through 2028. Another firm also highlighted US$15b to US$20b in revenue at risk from key drugs losing exclusivity over roughly the next three years and framed this as a key overhang for the stock, even while keeping a Neutral stance and the same US$25 target. These views point to a market that is still looking for clearer evidence that management can offset patent headwinds with new products and business development.

At the same time, some firms are focusing on company specific actions that could support execution. One research update pointed to Pfizer's obesity related deal as a positive step toward rebuilding the portfolio and addressing longer term LOE risk, even if more moves may be needed beyond 2028. Another raised its Pfizer price target by US$3, which implies a more constructive view on how current valuation lines up with prospects for new assets, cost discipline, or capital allocation, even though specific drivers were not detailed in the summary provided.

For investors, the key thread across these reports is that valuation is widely seen as appealing relative to the risks, but views still differ on how quickly Pfizer can prove out its next leg of growth. The research flow suggests that upcoming data, integration of deals, and visibility on replacing at risk revenue will be important catalysts for shifting sentiment either way.

Bullish Takeaways

Bullish analysts who lifted their Pfizer price target by US$3 signal that, at least for some, current valuation already reflects much of the LOE risk and leaves room for upside if execution on new products and deals holds up.
Positive comments around the recent obesity related deal suggest it could be a building block for longer term growth, which, if successful, may help investors get more comfortable with Pfizer's ability to offset post 2028 LOE exposure.
Several research notes describe Pfizer's valuation as compelling, which indicates that, for bullish analysts, the current P/E and earnings power from the existing portfolio and pipeline look attractive relative to perceived risks.
The focus on business development, such as licensing activity and obesity related transactions, is viewed by more optimistic analysts as evidence that Pfizer is actively working to refresh its portfolio, an effort that could support sentiment if those assets progress as planned.

What's in the News

Pfizer reaffirmed its 2026 revenue guidance at US$59.5b to US$62.5b, which factors in about US$5b from COVID 19 products and an estimated US$1.5b revenue impact from loss of exclusivity, as well as expected effects from Most Favored Nation drug pricing, TrumpRx and current tariffs.
The company revised its 2025 revenue outlook to approximately US$62.0b, compared with its prior range of US$61.0b to US$64.0b.
Phase 2b VESPER 3 data for obesity candidate PF 3944 showed up to 12.3% mean placebo adjusted weight loss at week 28 with monthly dosing, and Pfizer outlined plans for more than 20 obesity trials in 2026, including at least 10 Phase 3 studies.
Pfizer and Novavax signed a non exclusive license and option deal for Novavax's Matrix M adjuvant, giving Pfizer access for vaccines in up to two infectious disease areas, with Novavax set to receive a US$30m upfront payment in Q1 2026.
In a multi year collaboration with Cartography Biosciences, Pfizer gained rights to tumor selective antigens that may support future oncology programs, with Cartography eligible for up to US$65m in upfront, near term milestones and option payments and a total deal value that could exceed US$850m if all milestones are achieved.

Valuation Changes

Fair Value: nudged lower from $35.46 to about $34.98 per share, a small reduction of roughly 1.3%.
Discount Rate: held steady at about 6.98%, with no change in the rate used to discount future cash flows.
Revenue Growth: projected revenue trend softened slightly, shifting from about a 1.21% decline to roughly a 1.27% decline.
Net Profit Margin: moved marginally lower from about 19.23% to roughly 19.20%.
Future P/E: eased from about 21.48x to roughly 21.06x, indicating a modestly lower multiple applied to expected earnings.

64 views

Key Takeaways

Accelerated productivity, global commercial prioritization, and effective emerging market strategies may drive operating margin and revenue growth beyond prevailing forecasts.
Rapid regulatory advances, innovative cancer therapies, and strategic deals could position Pfizer as a leader in next-generation treatments and diversify future income streams.
Patent expirations, pricing pressures, and reliance on acquisitions over innovation threaten Pfizer's growth, margins, and competitive position amid rising global and domestic challenges.

Catalysts

About Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Analysts broadly agree that Pfizer's cost realignment and margin expansion are meaningful, but the combination of accelerated AI-powered productivity gains, early realization of manufacturing savings, and sharper global commercial prioritization could propel operating margins and EPS well above current expectations, especially as gross margin targets in the upper seventies are consistently met ahead of schedule.
While analyst consensus sees value in Pfizer's oncology R&D pipeline and upcoming launches, current market assumptions may grossly underestimate the collective impact of rapid regulatory progress, aggressive label expansions, and faster patient uptake across key assets like Elrexfio, SV, and Padcev, which could transform revenue growth and establish Pfizer as the leader in next-generation cancer therapies by 2030.
Pfizer's commercial strategy and global execution are unlocking outsized growth in emerging markets, where product launches are accelerating and access is expanding across geographies like Asia and Latin America; this positions the company to capture significant share of the rising demand for chronic and specialty therapeutics, driving durable revenue growth from a large and underpenetrated base.
With a growing aging population worldwide and rising incidence of chronic diseases, Pfizer's focused investments in high-need areas such as vaccines, cardiometabolic, and rare diseases-alongside its strong commercial execution-provide a foundation for recurring income streams and sustained double-digit top-line expansion that is not fully reflected in current valuations.
Pfizer's improved balance sheet, disciplined capital allocation, and active pursuit of valuable strategic deals (including business development in obesity, immunology, and Chinese partnerships) give the company unparalleled flexibility to deploy capital into new growth engines, which can further diversify revenues and rapidly grow earnings power beyond what consensus models reflect.

Pfizer Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Pfizer compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Pfizer's revenue will decrease by 0.9% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from 16.8% today to 23.1% in 3 years time.
The bullish analysts expect earnings to reach $15.1 billion (and earnings per share of $2.7) by about September 2028, up from $10.7 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 16.5x on those 2028 earnings, up from 13.1x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.0x.
Analysts expect the number of shares outstanding to grow by 0.33% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Pfizer Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Intensifying global pressure for lower drug prices, including U.S. government initiatives like the MFN and IRA Medicare Part D redesign, is causing increased manufacturer discounts and could materially constrain Pfizer's revenue growth and compress future net margins.
The company is approaching a period of major patent expirations on key blockbuster drugs such as Eliquis and Ibrance, with management acknowledging that losses of exclusivity will create significant headwinds and expose revenue and earnings to generic erosion in the coming years.
Pfizer's reliance on acquisitions and in-licensing (evidenced by focus on BD and recent Seagen and 3SBio deals) rather than organic R&D raises concerns about pipeline sustainability and may limit long-term top-line growth and future margin expansion if integration or asset ROI underperforms.
The rapid rise of Chinese biotech innovation and government support for local champions is intensifying global competition, threatening Pfizer's leadership in both innovation and commercial opportunities, which could ultimately impact revenue and long-term earnings power.
New healthcare cost-containment reforms, price negotiation policies, and expanded 340B discounting are increasingly shifting value away from manufacturers towards intermediaries and providers, resulting in increased pressure on Pfizer's U.S. net revenues and profit margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Pfizer is $35.77, which represents two standard deviations above the consensus price target of $28.86. This valuation is based on what can be assumed as the expectations of Pfizer's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $36.0, and the most bearish reporting a price target of just $24.0.
In order for you to agree with the bullish analysts, you'd need to believe that by 2028, revenues will be $65.5 billion, earnings will come to $15.1 billion, and it would be trading on a PE ratio of 16.5x, assuming you use a discount rate of 6.8%.
Given the current share price of $24.71, the bullish analyst price target of $35.77 is 30.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Pfizer?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Populations And Emerging Markets Will Unlock New Opportunities